Risk-benefit profiles associated with receiving Moderna COVID-19 (mRNA-1273) vaccine as an additional pre-booster dose in immune-mediated dermatologic disease patients with low SARS-CoV-2-specific immunity following the primary series: A prospective cohort study.

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

Keyphrases